Format
Sort by
Items per page

Send to

Choose Destination

Links from MedGen

Items: 1 to 20 of 41

1.

Aceruloplasminemia.

Kono S.

Curr Drug Targets. 2012 Aug;13(9):1190-9. Review.

PMID:
22515740
2.

Desferrioxamine treatment of aceruloplasminemia: Long-term follow-up.

Pan PL, Tang HH, Chen Q, Song W, Shang HF.

Mov Disord. 2011 Sep;26(11):2142-4. doi: 10.1002/mds.23797. No abstract available.

PMID:
21594898
3.

The oral iron chelator deferiprone protects against iron overload-induced retinal degeneration.

Hadziahmetovic M, Song Y, Wolkow N, Iacovelli J, Grieco S, Lee J, Lyubarsky A, Pratico D, Connelly J, Spino M, Harris ZL, Dunaief JL.

Invest Ophthalmol Vis Sci. 2011 Feb 16;52(2):959-68. doi: 10.1167/iovs.10-6207.

4.

Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation.

Finkenstedt A, Wolf E, Höfner E, Gasser BI, Bösch S, Bakry R, Creus M, Kremser C, Schocke M, Theurl M, Moser P, Schranz M, Bonn G, Poewe W, Vogel W, Janecke AR, Zoller H.

J Hepatol. 2010 Dec;53(6):1101-7. doi: 10.1016/j.jhep.2010.04.039.

5.

The neurological presentation of ceruloplasmin gene mutations.

McNeill A, Pandolfo M, Kuhn J, Shang H, Miyajima H.

Eur Neurol. 2008;60(4):200-5. doi: 10.1159/000148691. Review.

6.

Aceruloplasminaemia with progressive atrophy without brain iron overload: treatment with oral chelation.

Skidmore FM, Drago V, Foster P, Schmalfuss IM, Heilman KM, Streiff RR.

J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):467-70.

PMID:
17911185
7.

Treatment of symptomatic heterozygous aceruloplasminemia with oral zinc sulphate.

Kuhn J, Bewermeyer H, Miyajima H, Takahashi Y, Kuhn KF, Hoogenraad TU.

Brain Dev. 2007 Aug;29(7):450-3.

PMID:
17307325
8.

Novel mutation in the ceruloplasmin gene causing a cognitive and movement disorder with diabetes mellitus.

Shang HF, Jiang XF, Burgunder JM, Chen Q, Zhou D.

Mov Disord. 2006 Dec;21(12):2217-20.

PMID:
17013908
9.
10.

Hepatic iron overload associated with a decreased serum ceruloplasmin level in a novel clinical type of aceruloplasminemia.

Kono S, Suzuki H, Takahashi K, Takahashi Y, Shirakawa K, Murakawa Y, Yamaguchi S, Miyajima H.

Gastroenterology. 2006 Jul;131(1):240-5.

PMID:
16831606
11.

Biochemical features of ceruloplasmin gene mutations linked to aceruloplasminemia.

Kono S, Suzuki H, Oda T, Miyajima H, Takahashi Y, Shirakawa K, Ishikawa K, Kitagawa M.

Neuromolecular Med. 2006;8(3):361-74.

PMID:
16775387
12.

Molecular and pathological basis of aceruloplasminemia.

Kono S, Miyajima H.

Biol Res. 2006;39(1):15-23.

13.

Iron overload and antioxidative role of perivascular astrocytes in aceruloplasminemia.

Oide T, Yoshida K, Kaneko K, Ohta M, Arima K.

Neuropathol Appl Neurobiol. 2006 Apr;32(2):170-6.

PMID:
16599945
14.

Aceruloplasminemia in an asymptomatic patient with a new mutation. Diagnosis and family genetic analysis.

Pérez-Aguilar F, Burguera JA, Benlloch S, Berenguer M, Rayón JM.

J Hepatol. 2005 Jun;42(6):947-9.

PMID:
15885371
15.

Macular degeneration in a patient with aceruloplasminemia, a disease associated with retinal iron overload.

Dunaief JL, Richa C, Franks EP, Schultze RL, Aleman TS, Schenck JF, Zimmerman EA, Brooks DG.

Ophthalmology. 2005 Jun;112(6):1062-5.

PMID:
15882908
16.

Extrapyramidal and cerebellar movement disorder in association with heterozygous ceruloplasmin gene mutation.

Kuhn J, Miyajima H, Takahashi Y, Kunath B, Hartmann-Klosterkoetter U, Cooper-Mahkorn D, Schaefer M, Bewermeyer H.

J Neurol. 2005 Jan;252(1):111-3. No abstract available.

PMID:
15654567
17.

Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation.

Mariani R, Arosio C, Pelucchi S, Grisoli M, Piga A, Trombini P, Piperno A.

Gut. 2004 May;53(5):756-8.

18.

Aceruloplasminemia, an iron metabolic disorder.

Miyajima H.

Neuropathology. 2003 Dec;23(4):345-50.

PMID:
14719552
19.

Aceruloplasminemia with juvenile-onset diabetes mellitus caused by exon skipping in the ceruloplasmin gene.

Hatanaka Y, Okano T, Oda K, Yamamoto K, Yoshida K.

Intern Med. 2003 Jul;42(7):599-604.

Supplemental Content

Support Center